موقع حكومي رسمي تابع لحكومة المملكة العربية السعودية

الأربعاء 13 ربيع الأول 1448هـ

نسخة تجريبية

روابط المواقع الالكترونية الرسمية السعودية تنتهي بـ gov.sa

جميع روابط المواقع الرسمية التابعة للجهات الحكومية في المملكة العربية السعودية تنتهي بـ .gov.sa

المواقع الرسمية الآمنة تستخدم HTTPS

تحقق من أن الموقع يستخدم بروتوكول HTTPS

مسجل لدى هيئة الحكومة الرقمية برقم :

20250831619

اقتراحات

قائمة الدراسات السريرية المسجلة على الادوية

عرض 291 - 300 من 496

تصفية

عنوان الدراسة	داعم الدراسة	حالة الدراسة	دواء الدراسة	مرحلة الدراسة	رقم بروتوكول الدراسة	موقع الدراسة
Randomized, two-way, two-period, single oral dose, open-label, crossover, bioequivalence study to compare Narapril tablets (20 mg enalapril) Produced by Julphar / UAE versus Renitec® tablets (20 mg enalapril) Produced by Merck Sharp & Dohme / UK, in healthy subjects under fasting condition.	SFDA	Ongoing	Narapril	BE	14-2017	Saudi Ajal
Randomized, three-way, three-period, single oral dose, open-label, crossover, bioequivalence study to compare Torvacol tablets (20 mg atorvastatin) Produced by JPM / Jordan, versus Lipitor® tablets (20 mg atorvastatin) Produced by Pfizer / Irland in healthy subjects under fasting conditions.	SFDA	Ongoing	Torvacol	BE	15-2017	Saudi Ajal
Randomized, two-way, two-period, single oral dose, open-label, crossover, bioequivalence study to compare Amlodar Capsules (10 mg amlodipine) Produced by Dar AlDawa / Jordan versus Amlor® Capsules (10 mg amlodipine) Produced by Pfizer / KSA, in healthy subjects under fasting condition.	SFDA	Ongoing	Amlodar	BE	16-2017	Saudi Ajal
Randomized, two-way, two-period, single oral dose, open-label, crossover, bioequivalence study to compare Glibil tablets (5 mg glibenclamide) Produced by Hikma / Jordan versus Daonil® tablets (5 mg glibenclamide) Produced Sanofi-Aventis / Germany, in healthy subjects under fed condition.	SFDA	Ongoing	Glibil	BE	17-2017	Saudi Ajal
Randomized, two-way, two-period, single oral dose, open-label, crossover, bioequivalence study to compare Diatab tablets (5 mg glibenclamide) Produced by SPIMACO / KSA versus Daonil® tablets (5 mg glibenclamide) Produced by Sanofi- Aventis / Germany, in healthy subjects under fed condition.	SFDA	Ongoing	Diatab	BE	18-2017	Saudi Ajal
"DIREGL07563 RATIONAL studyAn obseRvationAl registry To assess urInary albumin evOlution in Saudi hyperteNsive patients with the current treatment local ALgorithm "	SANOFI	Ongoing	APROVEL / Irbesartan	4	3	King Abdulaziz University Hospital (Jeddah)
Grazoprevir/Elbasvir For Treatment Of Hepatitis C Virus Genotype 4 Post Kidney Transplant	King Faisal Specialist Hospital & Research Center (MSD grant)	Ongoing	Zepatier	4	2171009	King Faisal Specialist Hospital and Research Center (Riyadh)
Randomized, two-way, two-period, single oral dose, open-label, crossover, bioequivalence study to compare Solifenacin succinate film-coated tablets (10 mg solifenacin succinate) versus Vesicare® film-coated tablets (10 mg solifenacin succinate), in healthy subjects under fasting condition.	SPIMACO ADDWAEIH	Ongoing	solifenacin succinate	BE	Feb-17	Saudi Ajal
A phase III randomized open-label multi-center study of ruxolitinib vs. best available therapy in patients with corticosteroid-refractory chronic graft versus host disease after allogenic stem cell transplantation	Novartis	Ongoing	Ruxolitinib (INC424) (Jakavi)	3	CINC424D2301	King Faisal Specialist Hospital and Research Center (Riyadh)
Phase II/III randomized multicentre study comparing neoadjuvant chemoradiotherapy followed by consolidation chemotherapy to neoadjuvant chemoradiotherapy alone in non-metastatic rectal cancer patients.	King Abdullah Medical City, Makkah	Ongoing	Capecitabine / oxaliplatin / FOLINIC Acid / FLUOROURACIL	2	IRB#17-329 version2	King Abdullah Medical City (Makkah)